-- Hercules Metals (BIG.V) 週三宣布，將私募配售股票的融資規模從 2,320 萬美元提高至 3,150 萬美元。 該公司透過包銷私募配售方式，以每股 0.59 美元的價格向承銷商出售了 3,640 萬股股票，籌集了 2,140 萬美元。 該公司還計劃透過經紀商私募配售方式，以每股 0.59 美元的價格出售 1,700 萬股股票，籌集 1,000 萬美元。 Barrick Mining (ABX.TO) 擁有參與權以維持其在該公司的股份，但 Hercules 並未透露該公司是否計劃參與此次配售。 所得款項將用於勘探和開發其位於愛達荷州西部、全資擁有的 Hercules 礦產項目，以及滿足一般營運資金需求。 該公司股票在多倫多證券交易所創業板 (TSX Venture Exchange) 的最新報收於 0.63 美元，下跌 0.01 美元。
Price: $0.63, Change: $-0.01, Percent Change: -1.56%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%